MXPA03008623A - Combinacion farmaceutica para el tratamiento del cancer. - Google Patents

Combinacion farmaceutica para el tratamiento del cancer.

Info

Publication number
MXPA03008623A
MXPA03008623A MXPA03008623A MXPA03008623A MXPA03008623A MX PA03008623 A MXPA03008623 A MX PA03008623A MX PA03008623 A MXPA03008623 A MX PA03008623A MX PA03008623 A MXPA03008623 A MX PA03008623A MX PA03008623 A MXPA03008623 A MX PA03008623A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
pharmaceutical combinations
formula
therapeutic agent
Prior art date
Application number
MXPA03008623A
Other languages
English (en)
Inventor
J Giles Francis
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of MXPA03008623A publication Critical patent/MXPA03008623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

De acuerdo con la presente invencion se proporciona una combinacion farmaceutica util para el tratamiento de cancer que comprende al menos un compuesto activo de la formula (i): (ver formula) y al menos un agente terapeutico adicional seleccionado de un analogo de nucleosido y/o agentes quimioterapeuticos; y, un metodo para el tratamiento de un paciente que padece cancer que comprende al menos un compuesto activo de la formula (I), segun se definio anteriormente, y al menos un agente terapeutico adicional seleccionado de un analogo de nucleosido y/o agentes quimioterapeuticos.
MXPA03008623A 2001-03-23 2002-03-25 Combinacion farmaceutica para el tratamiento del cancer. MXPA03008623A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27797501P 2001-03-23 2001-03-23
US33060101P 2001-10-25 2001-10-25
PCT/CA2002/000426 WO2002076472A2 (en) 2001-03-23 2002-03-25 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs

Publications (1)

Publication Number Publication Date
MXPA03008623A true MXPA03008623A (es) 2004-05-21

Family

ID=26958821

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008623A MXPA03008623A (es) 2001-03-23 2002-03-25 Combinacion farmaceutica para el tratamiento del cancer.

Country Status (13)

Country Link
US (2) US6800639B2 (es)
EP (1) EP1370270B1 (es)
JP (1) JP4391087B2 (es)
KR (1) KR20040018341A (es)
AT (1) ATE450265T1 (es)
CA (1) CA2441568A1 (es)
DE (1) DE60234577D1 (es)
HU (1) HUP0400314A3 (es)
MX (1) MXPA03008623A (es)
NO (1) NO20034204L (es)
NZ (1) NZ528394A (es)
PL (1) PL365285A1 (es)
WO (1) WO2002076472A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
AU2003291882A1 (en) * 2002-12-06 2004-06-30 Shire Biochem Inc. Pharmaceutical combinations and methods for the treatment of leukemia
CA2527126A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
EP1670514B1 (en) * 2003-09-25 2010-06-23 Astellas Pharma Inc. Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
JP5241484B2 (ja) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP2009507918A (ja) 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
TWI621624B (zh) 2008-01-11 2018-04-21 瑞塔醫藥有限責任公司 合成的三萜系化合物及其使用於治療疾病之方法
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20100004193A1 (en) * 2008-07-07 2010-01-07 Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare Combination therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
MX357596B (es) 2010-04-12 2018-07-16 Reata Pharmaceuticals Inc Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes.
WO2014025961A1 (en) * 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
DE60042921D1 (de) * 1999-03-29 2009-10-22 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
AU2002212015B2 (en) * 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine

Also Published As

Publication number Publication date
HUP0400314A3 (en) 2006-02-28
HUP0400314A2 (hu) 2004-08-30
NO20034204L (no) 2003-11-21
US6800639B2 (en) 2004-10-05
JP4391087B2 (ja) 2009-12-24
NZ528394A (en) 2005-06-24
JP2004525142A (ja) 2004-08-19
US20030083316A1 (en) 2003-05-01
ATE450265T1 (de) 2009-12-15
NO20034204D0 (no) 2003-09-22
KR20040018341A (ko) 2004-03-03
WO2002076472A3 (en) 2003-04-10
US20050004081A1 (en) 2005-01-06
EP1370270A2 (en) 2003-12-17
EP1370270B1 (en) 2009-12-02
DE60234577D1 (de) 2010-01-14
WO2002076472A2 (en) 2002-10-03
PL365285A1 (en) 2004-12-27
CA2441568A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
MXPA04012965A (es) Inhibidores virales.
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
GB0225475D0 (en) Therapeutic agents
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
GB0005251D0 (en) Therapeutic compounds
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
PL367682A1 (en) Dolastatin 10 derivatives
MXPA03010761A (es) Combinaciones farmaceuticas.
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
GB0130677D0 (en) Medicaments and novel compounds
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
HK1063290A1 (en) Pharmaceutical formulations containing low concentrations of peroxide for treating or preventing vaginal infections.
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
ZA200201408B (en) Use of docetaxel for treating hepatocellular carcinoma.
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
GB0020504D0 (en) Therapeutic method
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
MXPA03006359A (es) Metodo para tratamiento del cancer.
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.

Legal Events

Date Code Title Description
FG Grant or registration